Comorbidities and Coexisting Conditions, Gambling Disorder
Conditions
Brief summary
The study is a pilot study (Total N=30), with at pre, weekly during treatment, post and at three-month follow-up.
Detailed description
Recruitment will be done through online advertisement via social media and gambling-related websites. Participants will self-referred to the study via a study dedicated website (www.spelstudien.se). Login to a treatment platform will be verified using double authentication (detailed description of the online platform is provided in the application to the Swedish Ethical Review Authority). Written information about the study will be provided on the web page. Consent will be done online, with the possibility for participants to download study information and consent. Consenting participants will start a screening procedure. After screening, participants will be contacted for a telephone assessment with a clinical psychologist. During this interview, participants will be assessed for GD with a diagnostic interview, as well as the inclusion criteria for utilization of Spelpaus. If meeting criteria for the study, participants will be referred to the baseline/ pre-measures - which will start with an additional informed consent for the treatment phase and the iCBT. Inclusion will be done after the completion of the informed consent and baseline/pre-measures. After that, participant will get access to the iCBT.
Interventions
BEHAVIORALiCBT for Gambling Disorder and psychiatric comorbidities
The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
Sponsors
Deakin University
Karolinska Institutet
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Screen positive for GD, as measured with the Gambling Disorder Identification Test (total score ≥20 GDIT). * Fulfilling GD, assessed according to the Structured Clinical Interview for Gambling Disorder (SCI-GD). * Utilization of Spelpaus (3 months from treatment start). * ≥18 years of age. * Able to provide digital informed consent. * Classified within pathways 2 or 3, as measured with the Gambling pathways Questionnaire (GPQ). * Screen positive for at least one common mental diagnosis in addition to GD, assessed according to the Web Screening Questionnaire (WSQ).
Exclusion criteria
* Other ongoing psychological treatment for GD. * Severe depression, screened according to the Montgomery Åsberg Depression Rating Scale (total score \>34 MADRS-S). * Suicidality, screening of ≥4 points on item 9 of the MADRS-S
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Gambling Symptom Assessment Scale | Six months after treatment cessation | Primary outcome will be gambling symptoms, measured with the the Gambling Symptom Assessment Scale. Minimum score is 0 and maximum score is 48, with higher scores indicated higher frequency of gambling symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The TimeLine Followback for gambling | Six months after treatment cessation | Gambling behavior (days per week gambled) will be measured with a self-report item adapted from the TimeLine Followback for gambling. |
| The Generalized Anxiety Disorder 7-itemscale | Six months after treatment cessation | Anxiety symptoms will be measured by the Generalized Anxiety Disorder 7-itemscale. |
| The Patient Health Questionnaire | Six months after treatment cessation | Depressive symptoms will be measured with the The Patient Health Questionnaire. |
| The Alcohol Use Disorders Identification Test | Six months after treatment cessation | Alcohol problems will be measured with the Alcohol Use Disorders Identification Test. |
| The Drug Use Disorders Identification Test | Six months after treatment cessation | Drug problems will be measured with the Drug Use Disorders Identification Test. |
Countries
Sweden
Contacts
Primary ContactOlof Molander
Outcome results
None listed